Understanding Pharmacokinetic Sampling when Personalising Drug Treatments: implications for analysis

Share Download as iCal file
Click the icons above to Share, Tweet or add this event to your calendar (iCal)
RSS local group meetings

Wednesday 14 February 2018, 03:00pm - 04:30pm

Location Room 9.87, Worsley Building, University of Leeds

Speakers and details of their talks are as follows:
Dr Nina Wilkinson (University of Newcastle) on behalf of BADBIR and BSTOP study groups, and the PSORT consortium
Personalising adalimumab treatment of patients with psoriasis: a UK, multi-centre, longitudinal observational cohort study 
Psoriasis is a common, chronic condition which affects the quality of life of more than one million people in the UK. Biological therapy has revolutionised the management of moderate to severe psoriasis, but not all patients respond and some lose response over time. Drug levels, which are strongly influenced by anti-drug antibodies (ADA), consistently correlate with treatment outcomes across multiple inflammatory diseases with limited data in psoriasis. The aim of this study was therefore to investigate the clinical utility of therapeutic drug monitoring to optimise outcomes in psoriasis, using the exemplar TNF antagonist, adalimumab. 
Adults enrolled onto the British Association of Dermatologists Biologic Interventions Register (BADBIR) were recruited into this UK, multi-centre observational cohort study (Biomarkers of Systemic Treatment Outcomes in Psoriasis; BSTOP 2011 onwards, n=60 participating centres).  Serial samples were taken during adalimumab therapy and analysed for adalimumab level and ADAs. 
Data from this cohort were used to determine: (i) the therapeutic range and; (ii) whether drug levels predict response at 6 months using both descriptive techniques and multivariable mixed effect regression models. 
PSORT is MRC funded and has industry partners who have contributed funding for this work.
Dr Joe Standing (UCL)
Pharmacometrics: Statistical Pharmacology
In this talk I will introduce nonlinear mixed effects (multi-level) modelling and how it is applied to pharmacokinetics and pharmacodynamics in drug development and beyond.  Worked examples will then be used to show how such approaches can reveal pitfalls of ignoring biological prior information on the system generating the data of interest, and also how the approach can be used to optimise clinical trial design and in personalised medicine.
Please note you do not need to be an RSS member to attend, all are welcome. The event is free to attend and there is no need to register. 

Contact https://sites.google.com/site/rssleedsbradford/home

Tea/coffee from 2.30pm

Organiser Name Isabelle Smith

Email Address This email address is being protected from spambots. You need JavaScript enabled to view it.

Organising Group(s) RSS Leeds/Bradford Local Group





Join the RSS

Join the RSS

Become part of an organisation which works to advance statistics and support statisticians

Copyright 2019 Royal Statistical Society. All Rights Reserved.
12 Errol Street, London, EC1Y 8LX. UK registered charity in England and Wales. No.306096

Twitter Facebook YouTube RSS feed RSS feed RSS newsletter

We use cookies to understand how you use our site and to improve your experience. By continuing to use our site, you accept our use of cookies and Terms of Use.